Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dialysability of the sugammadex-rocuronium complex in subjects with severe renal impairment
2007-006934-33Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Jan 2008
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Sugammadex in chronic kidney disease (CKD), sponsored by Organon & Co. Primary endpoint: Dialysability of the sugammadex-rocuronium complex. Started Jan 2008; status: completed.
02
Drugs
Sugammadex
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2007-006934-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006934-33.